IRRA's Net Profit Increases 924.6 Percent In 2024, This Is The Trigger

JAKARTA PT Itama Ranoraya Tbk (IRRA) announced the results of its performance and financial achievements in 2024.

IRRA managed to record a total revenue of IDR 977,488,301,788, which grew significantly by 40.38 percent compared to the previous year of IDR 696,303,792,495.

The net profit of this medical device distributor company

It was recorded at IDR 53,263,191,012, an increase of 924.6 percent compared to the previous year, with a net profit margin of 5.45 percent.

This achievement was driven by positive growth in all business segments and efficient operational cost management.

President Director of PT Itama Ranoraya Tbk, Heru Firdausi Syarif said, the company's performance throughout 2024 is a strong growth momentum.

"We are very pleased with the performance achievements we have achieved this year. Various strategic initiatives have gone according to plan and exceeded previously defined targets, including the addition of new partnerships with business partners that have great potential to expand market reach," said Heru.

IRRA has succeeded in achieving the previously set target, with an achievement rate of 96.13 percent.

This achievement underscores the company's consistency in achieving ambitious performance targets, driven by significant growth in various business segments.

The Segment of Medical Electronic Medical Devices Sterile contributed the most significantly with revenue reaching IDR 534,880,341,069.

Followed by the In Vitro Diagnostics segment which recorded revenue of IDR 351,940,992,988, while other health product segments contributed IDR 48,885,768,969 and the Medically Non-Electronic Medical Devices segment Steril contributed IDR 41,781,198,762.

This overall achievement was driven by high demand in the medical device market, which resulted in very positive sales.

It is also supported by the development of several new business lines that make a significant contribution to the company's performance.

At the end of December 2024, IRRA's cash flow was recorded to have a deficit of IDR 64,697,980,768, which was caused by the business expansion strategy being implemented by the company.

This expansion has an impact on increasing operational funding needs.

However, the company continues to carry out cash management carefully and effectively to ensure liquidity is well maintained.

In an effort to increase business sustainability and expand market share, IRRA is also targeting business growth through product expansion and which will be carried out in 2024.

This move is expected to boost the company's greater growth by 2025, in line with the realization and implementation of the initiative.

In addition, IRRA has also and will continue to expand product distribution networks to all regions in Indonesia, to ensure the accessibility of medical devices that can be reached in various regions.

"IRRA's performance during 2024 shows very positive results, can be seen from the significant increase in sales volume. This is driven by the application of appropriate strategic steps and the company's ability to adapt in the midst of market changes," added Heru.

The company will also focus on strengthening and expanding cooperation with new partners, as well as strengthening existing partnerships.

In addition, IRRA plans to add new branches in strategic locations throughout Indonesia.

The move is expected to open new opportunities that support the company's long-term revenue and profitability growth.

IRRA optimistis dapat menjaga momentum pertumbuhan yang berkelanjutan dan mencapai kinerja yang lebih baik di masa mendatang.

Sebagai distributor alat kesehatan, IRRA terus beradaptasi dengan perkembangan kebutuhan masyarakat, memastikan produk yang relevan tersedia untuk memenuhi permintaan pasar.

Dengan komitmen terhadap kualitas, pelayanan, dan inovasi, IRRA akan terus memberikan kontribusi positif bagi industri alat kesehatan Indonesia.

- https://voi.id/ekonomi/473428/di-tengah-tantangan-industri-2024-sig-jaga-konsistensi-menuju-bisnis-bahan-bangunan-berkelanjutan

- https://voi.id/ekonomi/473231/perang-dagang-as-memicu-pelemahan-rupiah-ibrahim-assuabi-rupiah-bisa-tembus-rp17-000

- https://voi.id/ekonomi/472569/pam-mineral-raup-laba-bersih-rp318-75-miliar-di-2024-naik-1-074-persen

[/see_also]

IRRA is optimistic that it can maintain a sustainable growth momentum and achieve better performance in the future.

As a distributor of medical devices, IRRA continues to adapt to the development of community needs, ensuring relevant products are available to meet market demand.

With a commitment to quality, service, and innovation, IRRA will continue to make a positive contribution to the Indonesian medical device industry.